Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease

CÉCILE GAUJOUX-VIALA, CECILIA GIAMPIETRO, THOMAS GAUJOUX, HANG-KORNG EA, CLÉMENT PRATI, PHILIPPE ORCEL, DANIEL WENDLING and FRÉDÉRIC LIOTÉ
The Journal of Rheumatology February 2012, 39 (2) 233-239; DOI: https://doi.org/10.3899/jrheum.110865
CÉCILE GAUJOUX-VIALA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cecile.gaujoux-viala@psl.aphp.fr
CECILIA GIAMPIETRO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THOMAS GAUJOUX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANG-KORNG EA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CLÉMENT PRATI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PHILIPPE ORCEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIEL WENDLING
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRÉDÉRIC LIOTÉ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

This article has a correction. Please see:

  • Errata - April 01, 2012

Abstract

Objective. To describe 3 cases of scleritis associated with etanercept use for rheumatoid arthritis (RA) and to review the literature related to inflammatory eye diseases associated with the use of etanercept.

Methods. Three cases of severe scleritis during etanercept therapy were analyzed. A systematic review of the literature in PubMed, Embase, and the Cochrane Library was performed, from 1962 to July 2010.

Results. Three patients with seropositive RA developed scleritis 7–28 months after initiation of etanercept, for the first time during their long-lasting disease. In all patients the underlying disease had responded well to anti-tumor necrosis factor therapy. Ocular inflammation went into remission after discontinuation of etanercept, and no other relapses were observed. One patient experienced a dechallenge-rechallenge phenomenon (improvement in symptoms following discontinuation of the agent, then reappearance or worsening of symptoms on reexposure to the agent). Forty-two cases of inflammatory eye diseases believed to be associated with the use of etanercept have been reported in the literature: 33 uveitis, 8 scleritis, 1 orbital myositis, concerning 16 patients with RA, 10 with juvenile idiopathic arthritis, 14 with ankylosing spondylitis, and 2 with psoriatic spondyloarthropathy. Dechallenge was performed in 28 patients, leading to resolution of symptoms. Rechallenge was done in 6 cases, with clear exacerbation.

Conclusion. Ocular inflammation is paradoxically a potential adverse effect of etanercept, even in previously uninvolved eyes.

Key Indexing Terms:
  • SCLERITIS
  • ETANERCEPT
  • RHEUMATOID ARTHRITIS

The widespread use of tumor necrosis factor-α (TNF-α) blockers has led to the recognition of paradoxical adverse effects, defined as the onset or exacerbation of disorders that are usually improved by TNF-α antagonists. Cutaneous psoriasis, Crohn’s disease, and uveitis exacerbations have been extensively reported. Scleritis, a serious and vision-threatening ocular disease, has recently been described as another possible paradoxical effect of anti-TNF-α agents and particularly of etanercept1. Scleritis is a destructive inflammatory eye disease characterized by scleral edema and inflammatory cell accumulation in the sclera. Untreated, the inflammatory process may extend to adjacent tissues, causing uveitis, glaucoma, retinal detachment, and perforation of the globe. About 50% of cases are idiopathic, with the majority of the others having an associated systemic connective tissue disorder. In about half of these patients, the systemic illness is a nodular seropositive RA. The overall prevalence of scleritis in patients with RA is reported to range from 0.67% to 6.3%2,3.

We describe 3 cases of severe anterior scleritis following the administration of etanercept for RA. The scleritis was temporally related to etanercept injections. Drug discontinuation resulted in rapid resolution. We systematically reviewed the literature concerning inflammatory eye disease associated with the use of etanercept: 42 cases were identified and will be reviewed.

MATERIALS AND METHODS

Study selection

A systematic literature search was performed in PubMed Medline, Embase, and Cochrane Library databases from 1962 to July 2010 without a limit on years of publication or journal, using the following key words: “scleritis” (MeSH Terms) OR “scleritis” (All Fields) OR “uveitis” (MeSH Terms) OR “uveitis” (All Fields) OR “orbital myositis” (MeSH Terms) OR “orbital” (All Fields) AND “myositis” (All Fields) OR “orbital myositis” (All Fields) OR ocular (All Fields) AND “inflammation” (MeSH Terms) OR “inflammation” (All Fields) AND “TNFR-Fc fusion protein” (Substance Name) OR “TNFR-Fc fusion protein” (All Fields) OR “etanercept” (All Fields). The limits were English or French languages. In addition, reference lists of the reports initially found were hand-searched to identify additional relevant reports. We also included abstracts of the American College of Rheumatology (ACR) and European League Against Rheumatism meetings from 2006 to 2010. The inclusion criteria were all articles with case reports of inflammatory eye disease with etanercept therapy. The exclusion criterion was a prior eye episode except in flares with dechallenge-rechallenge phenomenon.

Data collection

Two investigators (CGV, CG) selected the articles and collected the data, using a predetermined form. For each case report, these data were collected: demographic characteristics (sex, age), rheumatic disease features and duration, extraarticular manifestation, duration and dose of etanercept treatment before onset of inflammatory eye disease, type of ocular disease, dechallenge-rechallenge, and concomitant treatments [disease-modifying antirheumatic drugs (DMARD), corticosteroids, nonsteroidal anti-inflammatory drugs (NSAID), and bisphosphonates].

RESULTS

Case reports

We identified 3 patients, whose main characteristics were collected retrospectively. All patients had RA, fulfilling the 1989 ACR criteria and resistant to conventional treatment with DMARD.

Patient 1

A 71-year-old man with a 19-year history of positive rheumatoid factor (RF) and anticitrullinated protein antibodies had erosive RA at the time of introduction of etanercept in October 2006. He presented cutaneous nodules as an extraarticular manifestation. Etanercept was given at the dosage of 25 mg twice a week as monotherapy. The treatment was well tolerated and articular manifestations were in remission when unilateral scleritis with uveitis developed in February 2009. He was treated with topical applications of corticosteroids, without any improvement. In March 2009 etanercept was discontinued, with a rapid resolution of ocular symptoms. Three weeks later the sclero-uveitis had disappeared, but the underlying articular disease was in flare. Adalimumab (40 mg/2 weeks) was successful and no ocular relapse was observed at a 1-year followup.

Patient 2

A woman had a 20-year history of RF-positive RA associated with cutaneous nodules and a sicca syndrome. A history of cutaneous vasculitis was noted. She was successfully treated with etanercept 25 mg twice a week for 7 months before developing a bilateral necrotizing scleritis. Ocular manifestations were treated with topical corticosteroids, without success. Systemic corticotherapy was temporarily beneficial, with secondary relapses. Only discontinuation of etanercept allowed remission, after 1 year. She was subsequently treated with infliximab (5 mg/kg) for 4 years and adalimumab (40 mg/2 weeks) for 2 years, and is currently receiving rituximab. No new scleritis relapses were observed.

Patient 3

A 44-year-old woman had erosive RA with positive RF since 1994. She never had extraarticular manifestations. In August 2003, etanercept 25 mg subcutaneously (SC) twice weekly was started, resulting in a dramatic clinical improvement, and within 3 months she went into remission. In November 2005 she developed severe bilateral scleritis with moderate anterior uveitis. She noted a worsening of her eye pain temporally related to etanercept injections and an improvement after transitory (1 week) discontinuation. She was treated with oral indomethacin and topical corticosteroids without efficacy. In May 2006, etanercept was discontinued and her ocular symptoms markedly improved. Because the joint disease flared, she decided to restart etanercept. Within 24 hours she experienced a dramatic ocular inflammation. She was hospitalized and etanercept was withdrawn. Three months later she remained free of ocular inflammation, but the joint disease was still active, despite 2 infusions of 1000 mg rituximab.

Literature search results

Initially, 1056 potentially relevant articles were screened. Forty-two cases of inflammatory eye disease believed to be associated with the use of etanercept were identified. Figure 1 shows the selection process.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The process of the literature search. TNF: tumor necrosis factor.

Patient characteristics

There were 16 patients with RA, 10 with juvenile idiopathic arthritis (JIA), 14 with ankylosing spondylitis, and 2 with psoriatic arthritis. The characteristics of the patients are given in Table 1. Eye involvement included 33 cases of uveitis, 8 of scleritis, and 1 case of orbital myositis (Table 2). Mean age of the patients was 43.4 ± 13.6 years, and 78% were women. The mean rheumatic disease duration was 11.6 ± 8.9 years.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of patients with inflammatory eye disease associated with etanercept reported in the literature.

View this table:
  • View inline
  • View popup
Table 2.

Subtypes of inflammatory eye diseases associated with etanercept. Results are expressed as mean ± SD.

Drug administration and causality assessment

Etanercept was given according to current dosing, e.g., 25 mg SC twice a week in adults and 0.4 mg/kg for JIA. In 16 patients the dosage was not reported. The average time between the beginning of etanercept therapy and the onset of symptoms was 12.8 ± 9.2 months, with exposure times ranging between 1 and 36 months. Dechallenge (discontinuation of the agent) was performed in 28 patients, leading to resolution of symptoms. Rechallenge (reexposure to the agent) was done in 8 cases, with clear worsening of symptoms in 6 cases. Bisphosphonate use, which can induce uveitis flares, was reported in 1 patient.

DISCUSSION

The potential of anti-TNF-α agents in ophthalmology has been the subject of increasing interest in recent years. All anti-TNF-α drugs currently in clinical use, namely the monoclonal antibodies infliximab and adalimumab, as well as the soluble TNF receptor etanercept, have shown efficacy in treating not only joint inflammation, but also extraarticular manifestations, including uveitis and scleritis.

Saurenmann, et al4 and Tynjala, et al5 analyzed the effects of infliximab and etanercept in cases of childhood uveitis and found that although both agents seemed beneficial, infliximab was associated with better clinical responses in a larger percentage of patients. Braun, et al, using data from recently performed trials, found that reduction of the number of anterior uveitis flares by agents directed against TNF-α was slightly more marked among patients treated with infliximab, but this difference was not significant6. Guignard, et al7, in a retrospective study, and Cobo-Ibanez, et al8, in a prospective study, suggested that anti-TNF antibodies lowered the rate of uveitis flares in patients with spondyloarthropathy, whereas soluble receptor did not seem to lower this rate. Galor, et al9 found a statistically significant superiority of infliximab in the control of ocular inflammation in cases of refractory uveitis. Moreover, in a recent registry-based study, Lim, et al10 reported a significantly greater number of cases of uveitis with etanercept in comparison with infliximab and adalimumab. Based on the results derived from 16 patients with rheumatic diseases, Smith, et al suggested that etanercept has limited efficacy for ocular inflammation even when it has efficacy for systemic disease11. The information on adalimumab for ocular disease is still very limited, although recently Restrepo and Molina reported a successful treatment of severe nodular scleritis with this agent12.

The first hypothesis that we can formulate to explain ocular involvement despite articular improvement with etanercept is that antibody-based TNF-α inhibition is superior to receptor decoy therapy for the treatment of ocular inflammation occurring in the course of rheumatic disease.

The alternative hypothesis, supported by the dechallenge-rechallenge phenomenon observed, is that scleritis can be a paradoxical effect of etanercept. Attribution analysis proposed by Miller, et al13 is a method to evaluate the likelihood of an association between an environmental exposure and an adverse event in rheumatic-related disease. According to the criteria of Miller, the specified primary attribution elements include temporal association, lack of likely alternative explanations, dechallenge (improvement in symptoms following discontinuation of the agent), rechallenge (reappearance or worsening of symptoms on reexposure to the agent) and biological plausibility (the likelihood of the agent causing the signs and symptoms, based on its known in vivo and/or in vitro effects).

The 5 primary elements of the attribution analysis suggest a relationship between etanercept and scleritis. Regarding the temporal relationship, the average time between the beginning of therapy and the onset of symptoms was 12.8 months, with exposure times ranging between 1 and 36 months. Patient 3 developed notable worsening of scleritis the day following the administration of etanercept. No likely alternative explanations could be elicited, except RA. A critical attribution element was the dechallenge-rechallenge phenomenon. A rechallenge effect was noted in scleritis for the first time in Patient 3 as well as in the 6 cases of uveitis reported by Taban, et al14, Reddy and Backhouse15, Coates, et al16, Lim, et al10, and Galor, et al9. In our 3 patients and in 28 patients from the literature, withdrawal with or without other measures resulted in either complete or partial improvement of eye symptoms.

Concerning biological plausibility, difficulties in explaining the underlying pathogenetic mechanism of etanercept-induced scleritis arise from a limited knowledge of the physiopathology of scleritis. A study showed that ocular infiltrating T cells from patients with active uveitis stimulated in vitro with soluble TNF-α receptors began to synthesize TNF-α17. Soluble receptors influence TNF-α activity in vitro and in vivo and maintain the balance between active, free TNF-α and the inactive form bound to its soluble receptors. The soluble forms in high concentrations act as inhibitors by competing with TNF-α cell-surface receptors. However, in lower concentrations, soluble receptors can prolong the biologic half-life of TNF-α by functioning as a carrier protein, protecting TNF-α from degradation and therefore stabilizing its activity18.

Another explanation is that TNF-R p55 is the most biologically active of the 2 receptors but that TNF-R p75 has a 5-fold higher affinity for TNF-α. When TNF-α levels are low, p75 TNF-R facilitates p55 TNF-R activity possibly by a ligand-passing mechanism or as a result of intracellular kinase activation19. Increasing levels of soluble p75 TNF-R by administering etanercept (p75 receptor fusion protein), or decreasing levels of circulating TNF-α by administering infliximab, may interfere with immune homeostasis and disease pathogenesis by as-yet undefined mechanisms, to potentially exacerbate a patient’s underlying tendency to develop inflammatory ocular disease.

These case reports and review raise the possibility that etanercept may precipitate an inflammatory reaction in pre-disposed individuals. However, this review had some limitations, including the retrospective design, the small number of reports, multiple observers, variable followup intervals, heterogeneity of the form of ocular inflammation, the type of systemic association, the population characteristics, and the difficulty in distinguishing an ocular inflammation related to a joint disease and an adverse event.

Ocular inflammation is paradoxically a potential adverse effect of etanercept even in previously uninvolved eyes. Patients being treated with TNF-α soluble receptors should be closely monitored for the development of ocular signs and symptoms in order to detect flares secondary to etanercept therapy.

  • Accepted for publication September 20, 2011.

REFERENCES

  1. 1.↵
    1. Le Garrec J,
    2. Marcelli C,
    3. Mouriaux F
    . [Can tumor necrosis factor inhibitors induce sclero-uveitis?]. French. J Fr Ophtalmol 2009;32:511.e1–6.
    OpenUrl
  2. 2.↵
    1. Hamideh F,
    2. Prete PE
    . Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001;30:217–41.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Smith JR,
    2. Macksen F,
    3. Rosenbaum JT
    . Therapy insight: Scleritis and its relationships of systemic autoimmune disease. Nat Clin Pract Rheumatol 2007;3:219–26.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Saurenmann RK,
    2. Levin AV,
    3. Feldman BM,
    4. Laxer RM,
    5. Schneider R,
    6. Silverman ED
    . Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF-alpha agents. J Pediatr 2006;149:833–6.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Tynjala P,
    2. Lindahl P,
    3. Honkanen V,
    4. Lahdenne P,
    5. Kotaniemi K
    . Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548–50.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Braun J,
    2. Baraliakos X,
    3. Listing J,
    4. Sieper J
    . Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447–51.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Guignard S,
    2. Gossec L,
    3. Salliot C,
    4. Ruyssen-Witrand A,
    5. Luc M,
    6. Duclos M,
    7. et al.
    Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study. Ann Rheum Dis 2006;65:1631–4.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Cobo-Ibanez T,
    2. del Carmen Ordonez M,
    3. Munoz-Fernandez S,
    4. Madero-Prado R,
    5. Martin-Mola E
    . Do TNF-blockers reduce or induce uveitis? Rheumatology 2008;47:731–2.
    OpenUrlFREE Full Text
  9. 9.↵
    1. Galor A,
    2. Perez VL,
    3. Hammel JP,
    4. Lowder CY
    . Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317–23.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Lim LL,
    2. Fraunfelder FW,
    3. Rosenbaum JT
    . Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248–52.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Smith JR,
    2. Levinson RD,
    3. Holland GN,
    4. Jabs DA,
    5. Robinson MR,
    6. Whitcup SM,
    7. et al.
    Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252–7.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Restrepo JP,
    2. Molina MP
    . Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 2010;29:559–61.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Miller FW,
    2. Hess EV,
    3. Clauw DJ,
    4. Hertzman PA,
    5. Pincus T,
    6. Silver RM,
    7. et al.
    Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000;43:243–9.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Taban M,
    2. Dupps WJ,
    3. Mandell B,
    4. Perez VL
    . Etanercept (Enbrel)-associated inflammatory eye disease: Case report and review of the literature. Ocul Immunol Inflamm 2006;14:145–50.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Reddy AR,
    2. Backhouse OC
    . Does etanercept induce uveitis? Br J Ophthalmol 2003;87:925.
    OpenUrlFREE Full Text
  16. 16.↵
    1. Coates LC,
    2. McGonagle DG,
    3. Bennett AN,
    4. Emery P,
    5. Marzo-Ortega H
    . Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008;67:729–30.
    OpenUrlFREE Full Text
  17. 17.↵
    1. Sugita S,
    2. Takase H,
    3. Taguchi C,
    4. Mochizuki M
    . The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci 2007;48:3246–52.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Kollias G,
    2. Douni E,
    3. Kassiotis G,
    4. Kontoyiannis D
    . The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999;58 Suppl 1:I32–9.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Smith JR,
    2. Hart PH,
    3. Coster DJ,
    4. Williams KA
    . Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1998;39:658–61.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    1. Schmeling H,
    2. Horneff G
    . Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005;44:1008–11.
    OpenUrlAbstract/FREE Full Text
  21. 21.
    1. Kaipiainen-Seppanen O,
    2. Leino M
    . Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2003;62:88–9.
    OpenUrlFREE Full Text
  22. 22.
    1. Quartier P,
    2. Taupin P,
    3. Bourdeaut F,
    4. Lemelle I,
    5. Pillet P,
    6. Bost M,
    7. et al.
    Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093–101.
    OpenUrlCrossRefPubMed
  23. 23.
    1. Tiliakos AN,
    2. Tiliakos NA
    . Ocular inflammatory disease in patients with RA taking etanercept: Is discontinuation of etanercept necessary? J Rheumatol 2003;30:2727.
    OpenUrlFREE Full Text
  24. 24.
    1. Monnet D,
    2. Moachon L,
    3. Dougados M,
    4. Brezin AP
    . Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:393–7.
    OpenUrlCrossRefPubMed
  25. 25.
    1. Botsios C,
    2. Sfriso P,
    3. Ostuni PA,
    4. Todesco S,
    5. Punzi L
    . Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology 2007;46:1042–3.
    OpenUrlFREE Full Text
  26. 26.
    1. Caramaschi P,
    2. Biasi D,
    3. Carletto A,
    4. Bambara LM
    . Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol 2003;21:136–7.
    OpenUrlPubMed
  27. 27.
    1. Scrivo R,
    2. Spadaro A,
    3. Spinelli FR,
    4. Valesini G
    . Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008;58:1555–6; author reply 1556–7.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Wang F,
    2. Wang NS
    . Etanercept therapy-associated acute uveitis: A case report and literature review. Clin Exp Rheumatol 2009;27:838–9.
    OpenUrlPubMed
  29. 29.
    1. Fouache D,
    2. Goëb V,
    3. Massy-Guillemant N,
    4. Avenel G,
    5. Bacquet-Deschryver H,
    6. Kozyreff-Meurice,
    7. et al.
    Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: A retrospective study. Rheumatology 2009;48:761–4.
    OpenUrlAbstract/FREE Full Text
  30. 30.
    1. Martín-Mola E,
    2. Sieper J,
    3. Leirisalo-Repo M,
    4. Dijkmans BA,
    5. Vlahos B,
    6. Pedersen R,
    7. et al.
    Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:238–45.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 2
1 Feb 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease
CÉCILE GAUJOUX-VIALA, CECILIA GIAMPIETRO, THOMAS GAUJOUX, HANG-KORNG EA, CLÉMENT PRATI, PHILIPPE ORCEL, DANIEL WENDLING, FRÉDÉRIC LIOTÉ
The Journal of Rheumatology Feb 2012, 39 (2) 233-239; DOI: 10.3899/jrheum.110865

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease
CÉCILE GAUJOUX-VIALA, CECILIA GIAMPIETRO, THOMAS GAUJOUX, HANG-KORNG EA, CLÉMENT PRATI, PHILIPPE ORCEL, DANIEL WENDLING, FRÉDÉRIC LIOTÉ
The Journal of Rheumatology Feb 2012, 39 (2) 233-239; DOI: 10.3899/jrheum.110865
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Understanding the Psoriasis Phenotype Associated With Psoriatic Arthritis Using the PURE-4 Questionnaire: Insights From Spanish Real-World Settings
  • HLA-B27 Testing in Clinical Practice: A Retrospective Analysis of Testing Indications and Rheumatology Referral Patterns
  • Analysis of Gut-Homing Receptors in Circulating Mucosal-Associated Invariant T Cells and Their Presence in Synovial Tissue From Patients With Axial Spondyloarthritis
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire